Hyperway Pharmaceutical
- Biotech or pharma, therapeutic R&D
Founded in 2019, Hyperway Pharmaceuticals is a clinical-stage startup in Chengdu High Tech Development Zone, specializing in small molecule drug discovery and development. We focus on addressing unmet medical needs using advanced technologies, including our brain-penetrant platform.
In just a few years, we have grown to over 100 employees, building a strong pipeline in oncology, pain, and autoimmune diseases. Our leading candidates include HBW-3220, a 4th generation BTK inhibitor overcoming drug resistance, and HBW-004285, a non-addictive Nav1.8 inhibitor surpassing VX-548 in pharmacokinetics, safety, and onset speed. Additionally, HBW-3210, a brain-penetrant BTK inhibitor, has shown remarkable efficacy against brain tumors.
Hyperway is committed to advancing breakthrough medicines and welcomes collaborations to improve and extend patients' lives.
Address
ChengduSichuan
China
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}